Civitas Therapeutics, Inc., a biopharmaceutical company with a lead program in Parkinson's disease that utilizes the proprietary ARCUS respiratory delivery platform, has announced the appointment of Timothy S. Nelson as Chairman of the Board of Directors.
Civitas also announced that it has completed enrollment in its ongoing Phase 2b clinical study for its lead compound CVT-301, with data expected by the end of the first quarter of this year. CVT-301 is being developed as an adjunct, as needed (PRN) therapy to potentially provide rapid and reliable relief from intermittent debilitating motor fluctuations (OFF episodes) that affect many Parkinson's disease patients.
"Tim brings an exceptional track record of transformative leadership and company building across a broad range of therapeutic and medical device domains. His recent experience leading MAP Pharmaceuticals, initially as a privately-held platform company and ultimately as a publicly-traded late stage development company will be particularly relevant in helping to guide Civitas' continued growth," said Glenn Batchelder, Chief Executive Officer and Co- Founder of Civitas. "With our shared focus on improving patients' lives and his proven talent for building shareholder value, we are pleased to welcome Tim as Chairman of the Board."
"Civitas has a highly-validated drug inhalation platform, a potentially transformative Parkinson's therapy with important upcoming clinical data and a management team with an exceptional record of execution. This unique combination provides a strong foundation to build a company with a robust portfolio of differentiated therapies," said Nelson. "I am delighted to be joining the Civitas Board and look forward to supporting the team as they deliver on the company's remarkable promise."
In a release, the Company said that Nelson has more than 20 years of experience with drug delivery, medical devices and drug device combinations. Most recently he was Chief Executive Officer of MAP Pharmaceuticals, where he led the company through its initial public offering and developed LEVADEX, inhaled dihydoergotamine for migraine, through NDA filing (Allergan acquired MAP in March 2013). Prior to MAP, he served as Senior Vice President of Business and Commercial Development of Durect Corp. and previously held various positions at Medtronic including Business Director of Neurological Division for Europe, Middle East and Africa, and Manager of Drug Delivery Ventures and Business Development where he implemented growth initiatives for therapies treating a variety of medical disorders.
((Comments on this story may be sent to email@example.com))